142 related articles for article (PubMed ID: 29751136)
1. Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.
Codony-Servat J; García-Roman S; Molina-Vila MÁ; Bertran-Alamillo J; Giménez-Capitán A; Viteri S; Cardona AF; D'Hondt E; Karachaliou N; Rosell R
J Thorac Oncol; 2018 Sep; 13(9):1324-1337. PubMed ID: 29751136
[TBL] [Abstract][Full Text] [Related]
2. Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways.
García-Roman S; Garzón-Ibáñez M; Bertrán-Alamillo J; Jordana-Ariza N; Giménez-Capitán A; García-Peláez B; Vives-Usano M; Codony-Servat J; d'Hondt E; Rosell R; Molina-Vila MÁ
Transl Oncol; 2024 Feb; 40():101878. PubMed ID: 38183801
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
[TBL] [Abstract][Full Text] [Related]
4. Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells.
Codony-Servat J; García-Roman S; Molina-Vila MÁ; Bertran-Alamillo J; Viteri S; d'Hondt E; Rosell R
Transl Oncol; 2021 Jan; 14(1):100887. PubMed ID: 33129112
[TBL] [Abstract][Full Text] [Related]
5. The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.
Rodríguez-Abreu D; Cobo M; García-Román S; Viteri-Ramírez S; Jordana-Ariza N; García-Peláez B; Reguart N; Aguilar A; Codony-Servat J; Drozdowskyj A; Molina-Vila MA; d'Hondt E; Rosell R
Lung Cancer; 2022 Feb; 164():8-13. PubMed ID: 34971901
[TBL] [Abstract][Full Text] [Related]
6. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
7. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
Codony-Servat C; Codony-Servat J; Karachaliou N; Molina MA; Chaib I; Ramirez JL; de Los Llanos Gil M; Solca F; Bivona TG; Rosell R
Oncotarget; 2017 Jul; 8(29):47305-47316. PubMed ID: 28521301
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
9. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.
Huang Q; Wang Q; Li D; Wei X; Jia Y; Zhang Z; Ai B; Cao X; Guo T; Liao Y
J Exp Clin Cancer Res; 2019 Mar; 38(1):129. PubMed ID: 30876460
[TBL] [Abstract][Full Text] [Related]
12. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
13. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.
Wang J; Wang Y; Zheng C; Hou K; Zhang T; Qu X; Liu Y; Kang J; Hu X; Che X
Cell Biol Int; 2018 Sep; 42(10):1292-1299. PubMed ID: 29885023
[TBL] [Abstract][Full Text] [Related]
15. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
16. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
17. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
Ma P; Zhang M; Nie F; Huang Z; He J; Li W; Han L
Biomed Pharmacother; 2017 Mar; 87():20-26. PubMed ID: 28040594
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
